Darolutamide-based triple therapy combined with PSMA imaging guided focal treatment in patients with prostate cancer: a multicenter retrospective study
Darolutamide-based triplet therapy combined with PSMA-guided focal intervention achieved deep biochemical responses and durable disease control with manageable toxicity in real-world Chinese patients with mHSPC. The multicenter design and standardized methodology support the feasibility of this multimodal approach, which warrants validation in larger prospective studies.
Authors
- Yongbao Wei (ORCID: https://orcid.org/0000-0003-3114-9214)
- Liefu Ye (ORCID: https://orcid.org/0000-0002-4725-031X)
- Lin Deng (ORCID: https://orcid.org/0000-0002-7830-5969)
- Zhonglei Lu (ORCID: https://orcid.org/0000-0002-8915-4828)
- Dewen Zhong
- Jinfeng Wu (ORCID: https://orcid.org/0000-0002-6930-5465)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-1025-906X)
- Jinling Wu
- Zhixun Guo (ORCID: https://orcid.org/0000-0002-4474-5149)
- Qinfei Zhou
- Ruochen Zhang (ORCID: https://orcid.org/0000-0002-6814-0670)
- Zijun Zou
- Jiawen Wang (ORCID: https://orcid.org/0009-0005-2775-1845)
Institutions
- Fujian Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
- Guizhou Provincial People's Hospital (CN)
- Hangzhou Cancer Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.3389/fphar.2025.1692407
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Fujian Province
- National Science and Technology Major Project
- Medical Science and Technology Project of Zhejiang Province
- Science and Technology Program of Zhejiang Province